A photo of Parinda Mehta.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Professor, UC Department of Pediatrics

513-636-4913

513-803-1969

Board Certified

About Me

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Bone Marrow Transplantation BMT, Fanconi Anemia, Leukemia

My Locations

My Education

BA: Graduated from Parle College, Mumbai, India, 1988.

MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993.

Residency: Upstate Medical University (UMU) - State University of New York (SUNY), Syracuse, NY, 2002.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005.

Certification: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio.

My Publications

Selected Publication

Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Mehta, PA; Emoto, C; Fukuda, T; Seyboth, B; Teusink-Cross, A; Davies, SM; Wilhelm, J; Fuller, K; Vinks, AA; Boulad, F. Biology of Blood and Marrow Transplantation. 2019; 25:2416-2421.

Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Mehta, PA; Rotz, SJ; Majhail, NS. Biology of Blood and Marrow Transplantation. 2018; 24:e11-e19.

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Dvorak, CC; Satwani, P; Stieglitz, E; Cairo, MS; Dang, H; Pei, Q; Gao, Y; Wall, D; Mazor, T; Olshen, AB; et al. Pediatric Blood and Cancer. 2018; 65.

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Chandra, S; Fukuda, T; Mizuno, K; Davies, SM; Teusink-Cross, A; Tarin, R; Marsh, RA; Vinks, AA; Mehta, PA. Journal of Antimicrobial Chemotherapy. 2018; 73:1651-1658.

Model-informed precision dosing for alemtuzumab in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2021.

Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. British Journal of Clinical Pharmacology. 2021.

Comparison of the clinical phenotype and haematological course of siblings with Fanconi anaemia. Jung, M; Mehta, PA; Jiang, CS; Rosti, RO; Usleaman, G; da Rosa, JM C; Lach, FP; Goodridge, E; Auerbach, AD; Davies, SM; et al. British Journal of Haematology. 2021; 193:971-975.

Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. Khandelwal, P; Teusink-Cross, A; Kumar, AR; Bleesing, JJ; Mehta, PA; Jordan, MB; Chandra, S; Davies, SM; Marsh, RA. British Journal of Haematology. 2021.

Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. Zhao, J; Sharat, C; Mehta, PA; Mizuno, K; Vinks, AA; Setchell, KD R. Journal of Applied Laboratory Medicine. 2021; 6:625-636.

Ruxolitinib for the treatment of chronic GVHD and overlap syndrome in children and young adults. Wang, YM; Teusink-Cross, A; Elborai, Y; Krupski, MC; Nelson, AS; Grimley, MS; Flannery, A; Mehta, PA; Bleesing, JJ; Chandra, S; et al. Transplantation. 2021.